X-Square Capital’s Adaptimmune Therapeutics ADAP Stock Holding History

X-Square Capital’s Portfolio ADAP Stock Details ADAP Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	–	Sell	-11,359	Closed	–	–	165
2025 Q4	$0	Sell	11,359 -214	-2%	-$29	﹤0.01%	161
2025 Q3	$1K	Buy	11,573 +400	+4%	+$55	﹤0.01%	162
2025 Q2	$3K	Hold	11,173	–	–	﹤0.01%	160
2025 Q1	$2K	Hold	11,173	–	–	﹤0.01%	154
2024 Q4	$6K	Sell	11,173 -7	-0.1%	-$5	﹤0.01%	163
2024 Q3	$10K	Sell	11,180 -12	-0.1%	-$14	﹤0.01%	161
2024 Q2	$10K	Hold	11,192	–	–	﹤0.01%	157
2024 Q1	$14K	Sell	11,192 -16,233	-59%	-$19.6K	0.01%	153
2023 Q4	$22K	Buy	27,425 +654	+2%	+$369	0.01%	154
2023 Q3	$25K	Hold	26,771	–	–	0.02%	139
2023 Q2	$25K	Buy	+26,771	New	+$31.9K	0.02%	139

Other funds holding ADAP

RhumbLine Advisers Boston, Massachusetts $117B AUM 29.66% 1-Year Est. Return

X-Square Capital's ADAP Position: Q1 2026 in Review

X-Square Capital sold out of Adaptimmune Therapeutics (ADAP) in Q1 2026, closing a stake of 11,359 shares.

X-Square Capital first reported a position in ADAP in Q2 2023 and held it in 11 quarters. The position peaked at $25K in Q3 2023. 1 fund tracked by Wall St. Rank holds ADAP as of Q1 2026.

X-Square Capital reported no remaining Adaptimmune Therapeutics position as of Q1 2026 after selling out during the quarter.
X-Square Capital sold 11,359 Adaptimmune Therapeutics shares in Q1 2026.
X-Square Capital first reported a position in Adaptimmune Therapeutics in Q2 2023 and held it in 11 quarters.
X-Square Capital's Adaptimmune Therapeutics position peaked at $25K in Q3 2023.
1 fund tracked by Wall St. Rank held Adaptimmune Therapeutics as of Q1 2026.

Based on X-Square Capital's 13F filing for Q1 2026, filed 15 May 2026.